156 related articles for article (PubMed ID: 30955405)
41. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
42. Relation Between Delirium and Anticholinergic Drug Burden in a Cohort of Hospitalized Older Patients: An Observational Study.
Pasina L; Colzani L; Cortesi L; Tettamanti M; Zambon A; Nobili A; Mazzone A; Mazzola P; Annoni G; Bellelli G
Drugs Aging; 2019 Jan; 36(1):85-91. PubMed ID: 30484239
[TBL] [Abstract][Full Text] [Related]
43. Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Mac Donald R; Rutks I
Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
[TBL] [Abstract][Full Text] [Related]
44. Anticholinergic and sedative medications exposure in older patients: a cross-sectional study.
Zhang X; Zhou S; Li X; Zhou W; Zhou Y; Cui Y; Liu X
Int J Clin Pharm; 2019 Oct; 41(5):1152-1158. PubMed ID: 31392583
[TBL] [Abstract][Full Text] [Related]
45. Anticholinergic Prescribing in Medicare Part D Beneficiaries Residing in Nursing Homes: Results from a Retrospective Cross-Sectional Analysis of Medicare Data.
Niznik J; Zhao X; Jiang T; Hanlon JT; Aspinall SL; Thorpe J; Thorpe C
Drugs Aging; 2017 Dec; 34(12):925-939. PubMed ID: 29214512
[TBL] [Abstract][Full Text] [Related]
46. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
47. Prevalence, risk factors and adverse outcomes of anticholinergic burden in patients with advanced chronic conditions at hospital admission.
Sevilla-Sánchez D; Molist-Brunet N; González-Bueno J; Solà-Bonada N; Espaulella-Panicot J; Codina-Jané C
Geriatr Gerontol Int; 2018 Aug; 18(8):1159-1165. PubMed ID: 29644803
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of Anticholinergic Medication Use in the Program of All-Inclusive Care for the Elderly.
Covington LP; McCarrell J; Hoerster NS
Consult Pharm; 2016 Mar; 31(3):168-74. PubMed ID: 26975596
[TBL] [Abstract][Full Text] [Related]
49. Tamsulosin efficiency in treatment of benign prostatic hyperplasia evaluated by determining bladder weight.
Milicevic S
Med Arch; 2012; 66(6):391-5. PubMed ID: 23409519
[TBL] [Abstract][Full Text] [Related]
50. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
[TBL] [Abstract][Full Text] [Related]
51. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms.
Park YH; Kim TH; Lee SW; Chung BH; Cho JS; Lee JY
Low Urin Tract Symptoms; 2017 May; 9(2):75-81. PubMed ID: 28394492
[TBL] [Abstract][Full Text] [Related]
52. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
[TBL] [Abstract][Full Text] [Related]
53. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.
Pang R; Zhou XY; Wang X; Wang B; Yin XL; Bo H; Jung JH
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012336. PubMed ID: 33567116
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
[TBL] [Abstract][Full Text] [Related]
55. Anticholinergic and sedative drug burden in community-dwelling older people: a national database study.
Byrne CJ; Walsh C; Cahir C; Ryan C; Williams DJ; Bennett K
BMJ Open; 2018 Jul; 8(7):e022500. PubMed ID: 29982221
[TBL] [Abstract][Full Text] [Related]
56. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
57. Anticholinergic Burden in Children, Adults and Older Adults in Slovenia: A Nationwide Database Study.
Cebron Lipovec N; Jazbar J; Kos M
Sci Rep; 2020 Jun; 10(1):9337. PubMed ID: 32518392
[TBL] [Abstract][Full Text] [Related]
58. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
Narayan P; Lepor H
Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
[TBL] [Abstract][Full Text] [Related]
59. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
[TBL] [Abstract][Full Text] [Related]
60. Burden of benign prostatic hyperplasia among men in Japan: Patient-reported outcomes among those diagnosed and experiencing symptoms.
Yoshida M; Flores NM; Vietri J; Lee M; Murakami M
Int J Urol; 2015 Oct; 22(10):949-55. PubMed ID: 26138017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
